Srkalovic, G., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Mileham, K. F., Adesunloye, B., … Schilsky, R. L. (2025). Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In Cancer Research (Vol. 85, pp. CT226–CT226). American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.am2025-ct226

Srkalovic, Gordan, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Kathryn F. Mileham, Bamidele Adesunloye, Natalia Colocci, et al. “Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In Cancer Research, 85:CT226–CT226. American Association for Cancer Research (AACR), 2025. https://doi.org/10.1158/1538-7445.am2025-ct226.

Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Mileham KF, Adesunloye B, et al. Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In: Cancer Research. American Association for Cancer Research (AACR); 2025. p. CT226–CT226.

Srkalovic, Gordan, et al. “Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” Cancer Research, vol. 85, no. 8_Supplement_2, American Association for Cancer Research (AACR), 2025, pp. CT226–CT226. Crossref, doi:10.1158/1538-7445.am2025-ct226.

Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Mileham KF, Adesunloye B, Colocci N, Chen MD, Meric-Bernstam F, Pisick E, Marr AS, Benyounes A, Alese OB, Gregory A, Hinshaw DC, Grantham GN, Halabi S, Schilsky RL. Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. American Association for Cancer Research (AACR); 2025. p. CT226–CT226.